COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 4 FDA records to the applicant name Q-Med AB. It includes 2 original PMA approvals. 1 entry is a PMA supplement. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Aug 3, 2004 to Sep 18, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code LMH appears in 4 of the 4 linked filings. The collection spans 1 FDA product code and 2 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P030050, with 2 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 3 linked filings have a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: Seminariegatan 21, Uppsala, S-752 28. Recorded on P140029/S058, decision dated Sep 18, 2026.
Device categories in this collection
Implant, Dermal, For Aesthetic Use.
Changes described in PMA records
FDA’s recorded scope: approval for updated device labeling, including the addition of a statement regarding how the Restylane Contour is only for distribution to providers that have taken and successfully completed device-specific use training program when used for the correction of temple hollowing in patients over the age of 21.
Sep 18, 2026 · Normal 180 Day Track No User FeeThe FDA record for P030050/S056 lists a 30-day notice with decision OK30, dated 2026-09-17, for SCULPTRA (injectable poly-L lactic acid). The stated purpose is to modify compounding reactors R11 and R12 so they are consistent with reactor systems R11A and R12A. The supplement reason is given as a process change covering manufacturer, sterilizer, packager or supplier.
The filing does not describe how the reactors were changed, how R11A and R12A differ from R11 and R12, or what consistency means in engineering terms, so those details remain unknown. The stated purpose is a manufacturing change; it is not reported evidence of safety or clinical effectiveness. The identifier P030050 links the notice to the original PMA for this device, but a supplement is not an approval of the whole system.
FDA approval-order wording
Approval to modify compounding reactors R11 and R12 to be consistent with reactor systems R11A and R12A.
Sep 17, 2026 · 30-Day NoticeThe FDA database entry for P140029 records a December 9, 2016 approval for two dermal implants from Q-Med AB. Restylane Refyne is approved for injection into the mid-to-deep dermis to correct moderate to severe facial wrinkles and folds, such as nasolabial folds, in patients over 21. Restylane Defyne carries the same age and injection-depth language but is limited to moderate to severe, deep facial wrinkles and folds.
This entry is an original PMA approval, not a supplement or manufacturing notice. The statement reports the approved indications only; it does not provide independent evidence of safety or clinical effectiveness. No trial data, performance metrics, or comparative outcomes appear in the source fields.
FDA approval-order wording
Approval for Restylane Refyne is indicated for injection into the mid-to-deep dermis for the correction of moderate to severe facial wrinkles and folds (such as nasolabial folds) in patients over the age of 21. Restylane Defyne is indicated for injection into the mid-to-deep dermis for the correction of moderate to severe, deep facial wrinkles and folds (such as nasolabial folds) in patients over the age of 21.
Dec 9, 2016The August 3, 2004 approval for SCULPTRA (P030050) covers the device as intended for restoration and/or correction of the signs of facial fat loss, termed lipoatrophy, in people with human immunodeficiency virus. The applicant is Q-Med AB, and the product code LMH places it in the implant, dermal, for aesthetic use category under the general and plastic surgery specialty.
The decision field records an APPR outcome, but the supplement type and supplement reason fields are absent. This means the record does not state whether the action is an original PMA approval or a supplement, and no manufacturing or labeling change is described. The statement reports an intended use; it does not provide independent evidence of safety or clinical effectiveness.
FDA approval-order wording
APPROVAL FOR SCULPTRA. THE DEVICE IS INTENDED FOR RESTORATION AND/OR CORRECTION OF THE SIGNS OF FACIAL FAT LOSS (LIPOATROPHY) IN PEOPLE WITH HUMAN IMMUNODEFICIENCY VIRUS.
Aug 3, 2004Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.